Leidos (LDOS) › Analysis

Leidos (LDOS) stock analysis, November 3, 2026: A rally inside a downtrend stalls after earnings

Published November 3, 2026 · LDOS chart, levels and live analysis

Leidos Holdings, Inc. (LDOS) fell 6.1% to $135.39 on November 3, 2026, after reporting third-quarter earnings that beat on profit and came with enhanced full-year guidance. The drop followed a close at $144.16 the day before, the top of a 15% rally in a month that had carried the stock above its 200-day average. The weekly trend is still down. For the next two to six weeks the balance of evidence leans negative, with low conviction.

Why it matters

Leidos reported before the open on November 3: revenue of $4.63 billion, up 4%, net income of $413 million, or $3.28 per diluted share, and non-GAAP earnings per share up 19% to $3.62, according to the company. Profit cleared the $3.05 analysts expected, but revenue came in under the $4.71 billion they had pencilled in, and the main worry going in was margin pressure in the Health segment, as Investing.com noted.

The reaction says the good news was already in the price. The stock rose 15.3% over the past month into the report, then lost 6.08% on the day on volume 59% above its 20-day average. That is a heavy-volume reversal after a beat and a raised outlook. Nothing in the filings or headlines says exactly why it sold off. The revenue shortfall and the Health segment are the obvious candidates, but that is inference, not something the company or the press has confirmed.

The move was the stock's own. Over five days LDOS is down 2.7%, the S&P 500 (SPY) is down 2.1% and the tech sector fund XLK is down 7.1%, so the stock has held up 4.3 points better than its sector. On the day itself SPY gained 0.23% and XLK 1.08% while LDOS dropped. The week's damage came mostly from tech, and today's drop came from earnings.

The argument about LDOS has two sides. The constructive side is demand in defense and intelligence: Leidos is scaling cruise missile production under a framework for an initial 3,000 low-cost missiles, and it raised its quarterly dividend to $0.45 from $0.43. The cautious side is Health. Simply Wall St trimmed its fair value to $151.73 from $157.73, citing pressure there against strength elsewhere. On valuation, 15 analysts rate the stock a buy with a mean price target of $151.73, 10.8% above the current price. Targets run from $127 to $225, so even the most cautious one sits only just below the stock, while the most optimistic is far above it.

What the evidence says

The long-term thesis is weakened, not broken. The stock is 32% below its 52-week high of $199.55, down 24.7% year to date against gains of 10.5% for SPY and 22.3% for XLK, and below its 40-week average, so the weekly trend is down. The past month was a counter-trend rally from near the lower part of the range. It pushed the stock above its 10-week average and, on November 2, above the 200-day average at $140.62. Today's close put it back under that line.

For the next two to six weeks the balance of evidence leans negative, and conviction is low, at 1 of 4. The one clear signal is a rally inside a weekly downtrend that reached overbought, with the 14-day RSI at 72.5, and then failed at the 200-day average, where sellers have shown up on earlier rallies. The other two reasons point the same way: the stock has led SPY by 6.5% and XLK by 12.3% over 50 days, which is unusual strength for a stock in a downtrend and tends to fade. The case against is real. A beat, enhanced guidance and a dividend increase are not what a failing story looks like. The stock is still above its 50-day average at $129.30 and its 10-week average, and that relative strength could mean buyers are stepping in on weakness rather than leaving. Together these are why conviction is low and not higher. The failure at the 200-day line, on heavy volume, is what keeps the lean negative.

Levels that matter

The structure holds below $140.62, the 200-day average. The weekly trend is down, and that is where sellers have appeared on rallies, including this week. The trend would end only above $153.32, a swing zone, and a weekly close above it would be needed. The $150 round number sits just beneath it. Between $140.62 and $153.32 is a wide band where a rebound could run without changing the weekly picture.

The breakout level is a daily close below $134.20, a swing zone just under today's price. From there the first target is the 50-day average at $129.30 and the second is the $121.36 swing zone. The level where a breakout would be wrong is $141.78, which is the 200-day average plus a quarter of the 14-day ATR of $4.66. Against that stop the math gives 0.6 to 1 to the first target and 1.7 to 1 to the second. That does not reach the 3 to 1 that makes a breakout worth the risk. Only a target much lower, near the $111.53 swing zone, would bring the ratio close to that.

What would change the picture

A weekly close above $153.32 would end the weekly downtrend and turn the picture. The non-price fact that would do it is evidence that Health segment margins have stabilized in reported results, while defense and intelligence growth continues. That would remove the argument that offset a quarter of strong earnings today.

What to watch

Get a message when the LDOS picture changes — the agent team watches the levels and the news for you.Create a free account

More LDOS analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.